then maybe a liquidation is in order. There is really not much hope this will grow to any size that will garner major interest. If Becker can take it private it would be far easier to make other strategic purchases. As it is they have almost $1/share in cash and as usual they just sit on it rather than taking a confident approach to growing the company. At this rate their cash burn will slowly erode the cash as they have been doing for years with the shareholders left holding the bag. As I have said for years this management team is doing a poor job. Sorry to say you cannot take these people from large industry and expect them to understand how to work in small cap life science. It has not worked and I doubt it will ever work. The Klaus situation was a perfect example. He came from a huge company for some unknown reason with great fanfare and here we are years later with nothing to show for it but lower revenues, continued losses (that are growing) and now what do they do?
Surprising that the BD deal has not generated growth in the life sciences arena and this GAT, AGAT, whatever they want to call it is showing little value. In fact if you look back at all the PR they have put out you never hear about most of it again indicating it was all just hot air.